Outbreak of Cannabinoid-Associated Coagulopathy S ynthetic cannabinoids are a class of laboratorysynthesized drugs of abuse, commonly referred to as "spice" or "K2" and are designed to induce a calming sensation, while stimulating creativity and euphoria. They were first reported in Europe in the early 2000s and rapidly spread worldwide. 1, 2 Synthetic cannab inoids are commonly sprayed onto dried plant material to be smoked or prepared as a liquid to be vaporized. 1 Most forms are undetectable by traditional drugscreening methods and have been marketed legally as "not for human con sumption" to evade prosecution. 1, 2 Historically, synthetic cannabinoids have been associated with intracranial hemorrhage and immune thrombo cytopenia 3, 4 ; however, we found no previous re ports of synthetic cannabinoid-associated coagu lopathy in a review of the literature.
In March 2018, a series of patients presented to hospitals throughout Illinois with bleeding diathesis marked by persistent coagulopathy. 5 During the early stages of this outbreak, area physicians, in conjunction with the Illinois Poi son Center and the Illinois Department of Public Health, identified a possible correlation between coagulopathy and recent use of synthetic cannab inoids. 5, 6 Preliminary tests of patient serum samples revealed vitamin K antagonists, includ ing brodifacoum, bromadiolone, and difenacoum, as possible causes of coagulopathy. 6 Drug sam ples of the confiscated synthetic cannabinoids that were obtained in early arrests of the alleged drug distributors in this event were also positive for brodifacoum. 7 As of June 2018, a total of 164 cases of syn thetic cannabinoid-associated coagulopathy have been reported to the Illinois Department of Public Health. 5 Herein, we describe 34 patients who were identified as having synthetic cannabinoidassociated coagulopathy at our institution.
Me thods
Patients with synthetic cannabinoid-associated coagulopathy were identified during hospitaliza tion at Saint Francis Medical Center, a tertiary care hospital in Peoria, Illinois, between March 28 and April 21, 2018. The criteria used to diag nose synthetic cannabinoid-associated coagu lopathy are shown in Table 1 . 5, 6 All patients who met these criteria were included in this case 2 This test is used to detect warfarin, dicu marol, diphacinone, chlorophacinone, difenacoum, brodifacoum, and bromadiolone. None of these substances is a metabolite of another listed anti coagulant.
A datacollection form was developed for the systematic retrieval of anonymized epidemio logic, historical, diagnostic, and treatment data. This study was approved by the institutional re view board at the University of Illinois College of Medicine at Peoria.
R esult s

Presentation
A total of 34 patients met the criteria for likely synthetic cannabinoid-associated coagulopathy during 45 hospitalizations. The median age of the patients was 37 years (interquartile range, 27 to 46). A total of 24 patients (71%) were male, and 32 (94%) were white. The most common bleeding symptom in the patients at presenta
Major criteria
Presence of vitamin K-dependent factor coagulopathy (defined as a prothrom bin time of ≥14.8 seconds and an international normalized ratio of ≥1.3)
Recent exposure to synthetic cannabinoids (within the past 30 days)
Minor criteria
Active bleeding symptoms Exposure to contaminated synthetic cannabinoids obtained from a person with known superwarfarin poisoning Positivity for superwarfarin on anticoagulant poisoning panel
Confounding factor
Prescribed use of anticoagulants † * The Institutional Diagnostic Criteria for Synthetic Cannabinoid-Associated Coagulopathy are new criteria used by our team and institution to identify and treat patients presenting with classic symptoms, a history of consistent drug use, and coagulopathy on laboratory testing and were developed on the basis of recent reports 5, 6 and institutional experience. Patients who met both "major criteria" and at least one "minor criteria" were considered to have a clinical diagnosis of synthetic cannabinoid-associated coagulopathy. † If a patient used a prescribed anticoagulant, the diagnosis of synthetic cannabi noid-associated coagulopathy must be confirmed by an anticoagulant poison ing panel. Among 34 patients with synthetic cannabinoid-associated coagulopathy who accounted for 45 hospitalizations at Saint Francis Medical Center, a tertiary care hospital in Peoria, Illinois (admitted between March 28 and April 21, 2018), gross hematuria was the most common bleeding symptom at presentation, and abdominal pain was the most common nonbleeding symptom at presentation. The majority of patients presented with multiple bleeding symptoms, and only 1 patient did not present with bleeding symptoms. Outbreak of Cannabinoid-Associated Coagulopathy
The frequency of exposure to synthetic can nabinoids varied greatly, with 16 patients (47%) reporting daily use and 4 patients (12%) reporting firsttime use. The median number of days from the last reported ingestion of cannabinoid to hos pital admission was 1 day (interquartile range, 1 to 3). The specific synthetic cannabinoid com pounds associated with this outbreak have not yet been identified by public health organiza tions, although several commercial products, including one known as "Diablo," have been re ported.
8 Serum testing was not performed at our facility, and none of the patients consented to provide personal samples of synthetic cannabi noids for testing.
Vital signs in the patients at presentation were notable for elevated blood pressure (>130/80 mm Hg) in the case of 33 hospital admissions (73%), with a systolic blood pressure ranging from 108.3 to 206.0 mm Hg. 9 Five patients had body temperatures of 38°C or higher.
Hospitalization
Anemia (hemoglobin level, <13 g per deciliter in men and <12 g per deciliter in women) was noted during 13 hospitalizations (29%). Redcell transfusion was initiated in five patients (15%), either for active blood loss or for a hemoglobin level lower than 7 g per deciliter. Clinicians transfused a median of two units (range, one to six) of blood product. Leukocytosis (whitecell count, >12.0×10 3 cells per cubic millimeter) was noted during 24 hospitalizations (53%).
Microscopic urinalysis was performed during 42 of 45 hospitalizations, and 35 test results showed hematuria (≥50 red cells per highpower field) and 24 test results showed proteinuria (by urine dipstick testing). Mild, transient acute kidney injury was noted during 7 hospitaliza tions (16%).
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In several cases, imaging was performed to evaluate the presence of bleeding, especially in patients with severe abdominal or flank pain. The most common radiographic abnormalities were in the renal system, as seen on computed tomography in 12 of 23 patients; findings in cluded perinephric stranding, hyperemia, diffuse thickening, and dilatation of the urothelial col lecting system (Fig. S1 in the Supplementary Appendix, available with the full text of this ar ticle at NEJM.org).
Confirmatory anticoagulant testing was per formed in 15 of the 34 patients; tests were posi tive for brodifacoum in 15 patients (100%), dif enacoum in 5 (33%), bromadiolone in 2 (13%), and warfarin in 1 (7%) and were negative for dicumarol, diphacinone, and chlorophacinone in all patients tested. All patients who tested posi tive for warfarin, difenacoum, or bromadiolone also tested positive for brodifacoum. Management varied according to clinical pre sentation but was guided by recommendations from the Illinois Poison Center, guidelines for anticoagulant reversal, and case reports (Table S1A in the Supplementary Appendix).
6,1114 All patients received oral vitamin K 1 (phytonadione) therapy. Intravenous vitamin K 1 , redcell trans fusion, freshfrozen plasma infusion, 4factor prothrombin complex concentrate (which con tains the human coagulation factors II, VII, IX, and X) (Kcentra, Shire), or combinations of these treatments were used to reverse coagulopathy and treat bleeding, according to severity (Table  S2 in the Supplementary Appendix). Intravenous vitamin K 1 was administered in 23 patients (68%). Freshfrozen plasma infusion was per formed in 19 patients (56%), with a median of three units (range, two to six) delivered. One patient received Kcentra. The rates of early re sponse to each therapeutic combination were similar (Fig. 2) . Owing to the high cost of out patient oral vitamin K 1 therapy and limited ac cess to primary care, an interdisciplinary team that included physicians, case managers, thera pists, and pharmacists prepared the patients for safe discharge from the hospital (Table S1B in the Supplementary Appendix). This team pro vided discharge education to patients, interfaced with local pharmacies and insurance companies to address drug pricing, and arranged for deliv ery of oral vitamin K 1 to counter local shortages. They also coordinated outpatient followup visits at targeted local clinics and communicated with other facilities that reported similar cases.
Readmission and Outcomes
During the study, six patients were readmitted to the hospital. All these patients had left the hos pital against medical advice or had been unable to fill their prescription of oral vitamin K 1 because of the high cost or local shortage. Some alarm ing behaviors were noted among this subgroup, including recurrent use of the same batch of synthetic cannabinoids in two patients. One pa T h e ne w e ngl a nd jou r na l o f m e dicine Outbreak of Cannabinoid-Associated Coagulopathy tient had attempted to donate plasma and was readmitted to the hospital because of prolonged bleeding from the injection site. Treatment resulted in the cessation of bleed ing in each patient in our cohort, except in one patient who died during hospitalization (de scribed below); there were a total of four deaths statewide during the outbreak. Intracranial bleed ing is the only known bleeding symptom that has been associated with all events of death.
Case Report of One Death
A 37yearold woman without a known medical history presented to the emergency department with a Glasgow Coma Scale score of 4 (on a scale from 3 to 15, with lower scores indicating a reduced level of consciousness) and underwent urgent intubation for airway compromise. Recent use of synthetic cannabinoids and amphetamine was reported at admission by her friends who brought her to the hospital; they did not report known head trauma. History of coagulopathy was unknown at presentation. Family members later confirmed that there was no personal or family history of coagulopathy or prescribed use of anticoagulants.
The patient's body temperature in the emer gency department was 38°C. The patient had si nus tachycardia, with a heart rate of 128 beats per minute, a respiratory rate of 28 breaths per minute, and an oxygen saturation of 94% while breathing ambient air. The mean blood pressure during the first 3 hours after admission was 144.1/88.3 mm Hg. Laboratory testing revealed a prothrombin time greater than 150 seconds, an international normalized ratio higher than 20, and a hemoglobin level of 14.0 g per deciliter.
Computed tomography of the head without con trast material revealed acute intraparenchymal hemorrhage of the right basal nuclei and insula (7.2×3.7×3.4 cm) with intraventricular extension, a leftsided midline shift of 10 mm, and evidence of herniation.
The patient was administered 10 mg of intra venous vitamin K 1 , four units of freshfrozen plasma, and 2300 units of Kcentra. Three hours later, the international normalized ratio corrected to 1.1. On the basis of her clinical presentation, neurosurgical intervention was not initiated. Fifteen hours after presentation, she met criteria for brain death. 15 Organ donation was discussed with the patient's surrogate decision maker and the transplantation team. The surrogate decision maker elected to proceed with the organ dona tion because the coagulopathy had been effec tively controlled in the patient with the use of vitamin K 1 and because of the precedent for suc cessful organ transplantation in patients with superwarfarin poisoning. 16 
Discussion
Synthetic cannabinoids are psychotropic drugs that stimulate central and peripheral cannabi noid receptors; they have a higher affinity for cannabinoid1 (CB 1 ) receptors than for cannabi noid2 (CB 2 ) receptors. 1, 17, 18 The incidence of spe cific symptoms and toxic effects associated with acute synthetic cannabinoid intoxication varies according to the compound ingested but is typi cally associated with central CB 1 receptor ago nism. These symptoms and toxic effects include agitation, psychosis, cognitive impairment, respi ratory depression, hyperglycemia, leukocytosis, tachycardia, and hypertension. 1, 17 Both dependence and withdrawal syndromes have been described in patients with synthetic cannabinoid use. 17 Vitamin K antagonists inhibit vitamin K 2,3epoxide reductase, preventing activation of vitamin K 1 .
19 Vitamin K 1 is a necessary cofactor for γcarboxylation of clotting factors II, VII, IX, and X and proteins C and S. 19 The longeracting anticoagulants in this class, called superwarfa rins, are coumarin derivatives that were devel oped to counter warfarin resistance in rats. 11, 19 Brodifacoum has the highest potency in its class, with effects lasting 2 to 12 months. Coagulopa thy can persist even when serum levels of brodi facoum are undetectable, probably because he patic concentrations of brodifacoum can be up to 20 times as high as serum concentrations, without associated hepatotoxicity.
11,14,21,22 Gross hematuria is the most common hemorrhagic complication of superwarfarin toxicity; other hemorrhagic complications include mucosal bleed ing, epistaxis, and gastrointestinal bleeding. 19, 20, 23 Studies in rat models have shown that a bimodal pattern of hematuria -with early dosedepen dent transient hemoglobinuria and late recur rence of hematuria days after exposure -is a unique biomarker for brodifacoum poisoning. The suspected cause of hematuria is increased capillary permeability.
T h e ne w e ngl a nd jou r na l o f m e dicine been attributed to accidental ingestion by children and intentional ingestion by adults. 20, 23 There are few reported cases of transdermal or inhaled exposures, which were suspected to be occupa tional in origin. 24 Most of the patients in our co hort reported exposure by inhalation. The World Health Organization reported that brodifacoum toxicity in rat models is higher when the sub stance is inhaled than when ingested. 25 It is suspected that inhalation bypasses the firstpass hepatic metabolism, which results in more po tent systemic effects.
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Data from patients who use illicit drugs and have superwarfarinassociated coagulopathy are limited. In one case, a patient had prolonged coagulopathy for more than 400 days after he smoked "crack" cocaine that had been intention ally laced with brodifacoum in an attempt to potentiate the drug effects. 27 In a second case, toxic effects of brodifacoum were associated with cannabis use. 21 Although the previous cases were isolated, our case series of synthetic cannab inoid-associated coagulopathy is representative of a local case cluster.
To date, we could find no published explana tion for combining synthetic cannabinoids and superwarfarins. Historically, manufacturers of synthetic cannabinoids have experimented with their illicit drug products by adding agents to manipulate the cytochrome P450 system through competitive inhibition to potentially prolong the duration of the active form of the drug. 12, 18, 24, 28 Coumarin derivatives can also be used as scaf folding for ligands that can act at both CB 1 and CB 2 receptors for innumerable potential pharma cologic purposes. 29 Accidental contamination of naturally produced cannabinoids has been report ed (in particular, contamination due to the com mon use of rodenticides as crop protectants).
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There is also a potential for malicious contami nation, either by a drug manufacturing com petitor or as an act of bioterrorism. Brodifacoum has been flagged as an "agent of opportunity" because of its commercial availability and toxic potential and is tracked by the Department of Homeland Security and the Centers for Disease Control and Prevention. 23, 31 Reports from South Africa, Palestine, and other countries have de scribed brodifacoum used in chemical warfare. 23 The World Health Organization has also investi gated poisonings by warfarinlike compounds that were initially mistaken for viral hemor rhagic diseases. 23 In the affected population of synthetic cannabi noid users, there have been numerous barriers to longterm treatment. These include the lack of consensus guidelines and limited access to pri mary care after hospitalization, the latter of which makes close followup, frequent labora tory testing, and dose adjustment difficult. The cost and availability of longterm oral vitamin K 1 therapy, quoted to some of our patients as $24,000 to $34,000 (in U.S. dollars) per month, makes management difficult and underscores the value of confirmatory laboratory superwarfarin testing.
Our data indicate that superwarfarin adulter ants of synthetic cannabinoids can lead to clini cally significant coagulopathy. In our series, in most of the cases in which the patient presented with bleeding diathesis, symptoms were con trolled with the use of vitamin K 1 replacement therapy. However, four deaths have been reported statewide. 5 The means by which these adulter ants end up in synthetic cannabinoids are not known and are currently under investigation.
